Call our 24 hours, seven days a week helpline at 800.272.3900

24/7 Helpline 800.272.3900
Donate

CMS Decision on Treatment Coverage: What It Means for People Living with Alzheimer's

CMS Decision on Treatment Coverage: What It Means for People Living with Alzheimer's
Share or Print this page
Share or Print this page

The Centers for Medicare & Medicaid Services (CMS) issued a draft decision that essentially denies coverage of treatments targeting amyloid for Alzheimer’s disease, including aducanumab (Aduhelm), the first FDA-approved therapy to address the underlying biology of Alzheimer’s disease. The proposal deals a serious blow to everyone with dementia.

This decision must be reversed.

Take Action Now


FDA-approved Alzheimer’s treatments denied coverage

The CMS draft decision effectively denies Medicare coverage of FDA-approved medications for Alzheimer’s disease unless the person is enrolled in an approved clinical trial. This proposal severely restricts the number of people who could benefit from treatments today, and essentially blocks coverage of an entire class of potential future treatments designed to help those facing Alzheimer’s.

Medicare has always covered FDA-approved treatments for those living with other conditions like cancer, heart disease and HIV/AIDS. For CMS to treat those with Alzheimer’s disease differently than those with other diseases is unprecedented and unacceptable.

94% of American voters support Medicare coverage for aducanumab.

Source

New barriers to treatment

Alzheimer’s disease is a national crisis. But instead of addressing it in a thoughtful, effective and equitable manner, CMS is building barriers between the first treatments to bring relief and the people who are desperate for it.

With the proposed approach, only the privileged few with access to research institutions would have access to treatment — a move that will exacerbate and create further health inequities among those who are already disproportionately impacted by this fatal disease.

 

Listen to the real consequences of this decision for people living with Alzheimer’s.

What you can do

CMS must change its draft decision, which discriminates against people with Alzheimer's disease. The Alzheimer's Association calls on CMS and the Biden administration to hear the needs of people living with dementia and their caregivers. We need your help to make sure they’re listening — make your voice heard.

More information

 

Facts and Figures

1 in 3 seniors dies with Alzheimer’s or another dementia. It kills more than breast cancer and prostate cancer combined. Get the facts about this devastating disease.

 

Our Commitment to Transparency

The Alzheimer’s Association received less than 1% of its total 2021 contributed revenue from the biotechnology, pharmaceutical, diagnostics and clinical research industry.

 

Treatments for Alzheimer’s

There’s no cure for Alzheimer’s, but aducanumab addresses the underlying biology of the disease, and other medications and non-drug options may help lessen symptoms.

About the Alzheimer’s Association

The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®.

Keep Up With Alzheimer’s News and Events